BP709

テノキシカム

British Pharmacopoeia (BP) Reference Standard

• 別名: 4-ヒドロキシ-2-メチル-N-2-ピリジニル-2H-チエノ(2,3-e)-1,2-チアジン-3-カルボキサミド 1,1-ジオキシド
• 実験式（ヒル表記法）: C₁₃H₁₁N₃O₄S₂
• CAS番号: 59804-37-4
• 分子量: 337.37
• MDL番号: MFCD00083502
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• グレード: pharmaceutical primary standard
• APIファミリー: tenoxicam
• フォーム: crystalline powder
• シェルフライフ: limited shelf life, expiry date on the label
• メーカー／製品名: BP
• アプリケーション: pharmaceutical; pharmaceutical small molecule
• フォーマット: mixture
• SMILES記法: O=C(NC1=NC=CC=C1)C2=C(O)C(SC=C3)=C3S(N2C)(=O)=O
• InChI: 1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
• InChI Key: LZNWYQJJBLGYLT-UHFFFAOYSA-N

詳細

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Tenoxicam degradation impurity standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Tenoxicam Tablets

Tenoxicam Injection

生物化学的／生理学的作用

腎および肝毒性の比較的低い非ステロイド性抗炎症薬(NSAID)です。

包装

Unit quantity: 25 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

その他情報

Sales restrictions may apply.

安全性情報

• ピクトグラム: GHS06
• シグナルワード: Danger
• 危険有害性情報: H301 + H311 + H331
• 注意書き: P261 - P264 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P403 + P233
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable